CELU Stock Overview A clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Celularity Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Celularity Historical stock prices Current Share Price US$2.33 52 Week High US$7.97 52 Week Low US$1.30 Beta 0.64 1 Month Change -15.58% 3 Month Change -19.10% 1 Year Change 29.44% 3 Year Change -95.04% 5 Year Change -97.66% Change since IPO -97.62%
Recent News & Updates
Celularity Inc. Announces Receipt of Nasdaq Notification Nov 28
Celularity Announces Resolution of Nasdaq Listing Compliance Matter Nov 19
Celularity Inc. announced delayed 10-Q filing Nov 16
Celularity Inc., Annual General Meeting, Dec 19, 2024 Nov 11 Celularity Inc. Raises Earnings Guidance for the Full Year of 2024
Celularity Inc. (NasdaqCM:CELU) acquired Rebound and its certain related assets from Sequence LifeScience, Inc. for $5.5 million. Oct 17 See more updates
Celularity Inc. Announces Receipt of Nasdaq Notification Nov 28
Celularity Announces Resolution of Nasdaq Listing Compliance Matter Nov 19
Celularity Inc. announced delayed 10-Q filing Nov 16
Celularity Inc., Annual General Meeting, Dec 19, 2024 Nov 11 Celularity Inc. Raises Earnings Guidance for the Full Year of 2024
Celularity Inc. (NasdaqCM:CELU) acquired Rebound and its certain related assets from Sequence LifeScience, Inc. for $5.5 million. Oct 17
Celularity Inc. Appoints Richard J. Berman to Its Board of Directors Aug 29
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing Aug 25 Celularity Inc. announced delayed 10-Q filing Aug 17
Celularity Inc. Revises Sales Guidance for the First Quarter of 2024 Aug 01 Celularity Inc. Revises Sales Guidance for the First Quarter of 2024
Celularity Presents Data of the Effect of Its T-Cell Platform on Multiple Hematological and Solid Tumors At the American Society of Clinical Oncology (Asco) Annual Meeting Jun 05
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing May 25 Celularity Inc. announced delayed 10-Q filing May 17
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing Apr 23 Celularity Inc. announced delayed annual 10-K filing Apr 02
Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance 3L Mar 28
Celularity Inc. (NASDAQ:CELU) Held Back By Insufficient Growth Even After Shares Climb 80% Feb 14
High number of new and inexperienced directors Feb 14
Celularity Inc. Provides Sales Guidance for the First Quarter and Full Year 2024 Feb 02 Genting Berhad Engages in Discussions with Celularity Inc
Celularity Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2023 Jan 04
Celularity Inc. Announces Resignation of Robin L. Smith, MD, from Board of Directors Dec 30
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing Nov 26
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing Nov 25
Celularity Inc. announced delayed 10-Q filing Nov 15
Lim Kok Thay Notifies Celularity Inc. of His Intention to Resign as a Member of the Board and All Committees Sep 21
Celularity Inc. Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors Sep 08
New major risk - Financial position Aug 16
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Aug 16
High number of new and inexperienced directors Aug 16
Celularity Inc. to Present Data from a New Product Technology in Development for Orthopedic Applications at 7th International Conference on Orthopedics Jun 30
New major risk - Share price stability Jun 09
Celularity Inc. Announces Results from Exploratory Analysis of Phase 1 Data Evaluating Alterations in Gene and Protein Signatures Associated with Inflammation and Fistula Formation in Patients with Crohn's Disease May 20 Celularity Inc. announced delayed 10-Q filing May 16
Price target decreased by 24% to US$8.63 Apr 06
Consensus revenue estimates decrease by 36%, EPS upgraded Apr 05
Independent Director exercised options to buy US$822k worth of stock. Feb 16
Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction for Its Investigational Celularity Tendon Wrap (Ctw) Feb 02 Celularity Inc. Announces the Suspends of Robert Hariri as Chairman
Price target decreased by 12% to US$9.50 Jan 30
Celularity Inc. Announces in A Preclinical in Vivo Study of Placental Extracellular Matrix Jan 27
Celularity Inc.'s Placental-Derived Allogeneic Cell Therapy Provides Clinically Meaningful Benefit and Durable Biological Effect in Patients with Moderate to Severe Crohn's Disease in Phase 1, Phase 1b/2a and Phase 1b Studies Jan 07
Celularity Inc. Appoints Paul Graves as Chief Communications Officer Jan 05
Consensus forecasts updated Dec 09
Celularity Inc. Announces Halal Certification of Its Advanced Cellular Therapeutics, Biomaterial Products and Business Model Dec 06
Founder recently bought US$70k worth of stock Dec 01
Consensus forecasts updated Nov 19
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 16
High number of new and inexperienced directors Nov 16
Third quarter 2022 earnings released: EPS: US$0.034 (vs US$0.47 in 3Q 2021) Nov 11
Imugene’s on CARlytics Combination with Celularity’s Placental-derived off-the-shelf Allogeneic CYCART-19 T Cells Preclinical Data Presented at SITC Annual Meeting Nov 11
Investor sentiment deteriorated over the past week Nov 10
Investor sentiment deteriorated over the past week Oct 11
Celularity Promotes Two Executives in Executive Leadership Team Oct 07
Celularity Appoints Adrian Kilcoyne as Executive Vice President, Chief Medical Officer and Head of Global Affairs, Patient Safety and Patient Affairs Oct 04
Celularity appoints Adrian Kilcoyne as chief medical officer Oct 03
Celularity Inc. Publishes New Data in Frontiers in Immunology Demonstrating Placental-Derived Natural Killer Cells (CYNK) Recognized and Eliminated Influenza A Virus (IAV)-Infected Cells in Vitro Sep 27
Celularity Inc. Announces Resignation of Andrew L. Pecora, M.D., F.A.C.P., as Company’s President Effective as of August 31, 2022 Sep 24
Celularity falls after announcing fund raising deal Sep 15
Investor sentiment deteriorated over the past week Sep 12
High number of new and inexperienced directors Sep 09
Celularity falls 10% on deal for $150M common stock offering Sep 08
Founder exercised options to buy US$343k worth of stock. Aug 27
Price target decreased to US$10.60 Aug 23
Consensus forecasts updated Aug 16
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 10
Celularity Inc. Announces Treatment of First Patient in Phase 1/2a Clinical Trial for NK Cell Therapy CYNK-101, in Development for the First-Line Treatment of Advanced HER2 Positive Gastric and Gastroesophageal Junction (G/GEJ) Cancers Jul 28
Celularity begins phase 1/2a trial for cell therapy CYNK-101 to treat cancers Jul 27
Celularity Inc. Announces the Resignation of Andrew L. Pecora as President, Effective from August 31, 2022 Jul 22
Price target increased to US$11.80 Jun 23
Celularity Inc. Announces Board Changes Jun 05 Celularity Inc. Appoints Diane Parks to Board of Directors Celularity Inc. announced that it has received $30.000007 million in funding May 29
Consensus estimates of losses per share improve by 34% May 23 Celularity Inc. announced that it expects to receive $30.000007 million in funding May 20
First quarter 2022 earnings: Revenues exceed analyst expectations May 17
Consensus forecasts updated Apr 07
Full year 2021 earnings: EPS and revenues exceed analyst expectations Apr 02
Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers Jan 19
Celularity Inc. Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML Dec 29
Consensus forecasts updated Dec 23 Shareholder Returns CELU US Biotechs US Market 7D 5.0% -3.6% -2.4% 1Y 29.4% -2.6% 23.4%
See full shareholder returns
Return vs Market: CELU exceeded the US Market which returned 23.4% over the past year.
Price Volatility Is CELU's price volatile compared to industry and market? CELU volatility CELU Average Weekly Movement 37.1% Biotechs Industry Average Movement 10.8% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.1%
Stable Share Price: CELU's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CELU's weekly volatility has increased from 24% to 37% over the past year.
About the Company Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. The company operates through Cell Therapy, Degenerative Disease, and BioBanking segments. Its lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn’s disease.
Show more Celularity Inc. Fundamentals Summary How do Celularity's earnings and revenue compare to its market cap? CELU fundamental statistics Market cap US$52.39m Earnings (TTM ) -US$35.05m Revenue (TTM ) US$48.20m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CELU income statement (TTM ) Revenue US$48.20m Cost of Revenue US$17.26m Gross Profit US$30.95m Other Expenses US$66.00m Earnings -US$35.05m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.56 Gross Margin 64.20% Net Profit Margin -72.72% Debt/Equity Ratio 246.6%
How did CELU perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 11:32 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Celularity Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Molloy Alliance Global Partners Thomas Shrader BTIG Swayampakula Ramakanth H.C. Wainwright & Co.
Show 3 more analysts 
